Vetter’s Development Service Doubles its Revenues and Grows its Capabilities
News Sep 28, 2012
Vetter reports that its Development Service doubled its revenues over the last five years, due to increased customer demand for support on complex biologics.
Vetter Development Service (VDS) supports products from preclinical development through Phase III and develops robust processes that enable a seamless transfer to Vetter Commercial Manufacturing.
Offering a continuum of service, the global VDS organization comprises more than 150 scientists, engineers and other personnel.
Vetter’s Chicago facility provides early-stage clinical production, featuring equipment optimized for small-batch manufacturing.
Ravensburg facilities support a range of development products through Phase III and feature sophisticated new technologies with enhanced analytical capabilities.
One-year anniversary: Chicago
Since the full operational launch of VDS Chicago, Vetter´s first U.S. facility, in October 2011, the site has contracted with a number of companies from around the globe, including Belgium, Israel and Korea, in addition to the United States.
Supporting preclinical through Phase II products, the site has already released customer batches for clinical trials.
Over the past few months, the Chicago site has expanded analytical and microbial testing; added 2,000 square feet of GMP storage; and built out its business office to accommodate more than 20 additional work spaces.
Future plans include adding a third cleanroom to the two existing ones, which will expand current operations and provide filling of pre-sterilized syringes.
New analytics: Ravensburg
As part of its continuous investment in its facilities, over the last year Vetter acquired sophisticated new technologies at its Ravensburg development labs that enable better control of syringe and cartridge siliconization; more-accurate detection of sub-visible particles in drug products; and a greater ability to simulate commercial-level processes in the VDS setting, for even smoother product transfer to commercial production.
Said Paul Nelles, Ph.D., Vice President of Vetter Development Service, “The growth of VDS demonstrates the increasing need for expert support in the development of complex compounds, to address a growing market. This rise in demand confirms our decision to expand Vetter Development Service to North America, as was urged by our U.S.-based customers.”
Upcoming conference participation
Vetter will exhibit its development service portfolio at:
• CPhI / iCSE, October 9 - 11, Madrid, Spain, booth 10E83
• AAPS Annual Meeting, October 14 - 18, Chicago, booth 5020
• PDA, The Universe of Pre-Filled Syringes & Injection Devices, October 15 - 17, Las Vegas, booth 207
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018